Hend Fayez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hend Fayez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Adli AbdAllah Selim
Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
1 shared publication - Baher A. Daihom
Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo 11562, Egypt
1 shared publication - Faten Farouk
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th October City, Egypt
1 shared publication - Hassan Medhat Rashed
Atomic Energy Authority
1 shared publication I.T. Ibrahim
Egyptian Atom Energy Author, Hot Labs Ctr, Radio Labeled Cpds Dept, POB 13759, Cairo, Egypt
1 shared publication- Iman Saad Ahmed
Department of Pharmaceutics & Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 29 January 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 107
Nanoparticle-Mediated Dual Targeting: An Approach for Enhanced Baicalin Delivery to the Liver
In this study, water-soluble chitosan lactate (CL) was reacted with lactobionic acid (LA), a disaccharide with remarkable affinity to hepatic asialoglycoprotein (ASGP) receptors, to form dual liver-targeting LA-modified-CL polymer for site-specific drug delivery to the liver. The synthesized polymer was used to encapsulate baicalin (BA), a promising bioactive flavonoid with pH-dependent solubility, into ultrahigh drug-loaded nanoparticles (NPs) via the ionic gelation method. The successful chemical conjugation of LA with CL was tested and the formulated drug-loaded LA-modified-CL-NPs were assessed in terms of particle size (PS), encapsulation efficiency (EE) and zeta potential (ZP) using full factorial design. The in vivo biodistribution and pharmacokinetics of the designed NPs were assessed using 99mTc-radiolabeled BA following oral administration to mice and results were compared to 99mTc-BA-loaded-LA-free-NPs and 99mTc-BA solution as controls. Results showed that the chemical modification of CL with LA was successfully achieved and the method of preparation of the optimized NPs was very efficient in encapsulating BA into nearly spherical particles with an extremely high EE exceeding 90%. The optimized BA-loaded-LA-modified-CL-NPs showed an average PS of 490 nm, EE of 93.7% and ZP of 48.1 mV. Oral administration of 99mTc-BA-loaded-LA-modified-CL-NPs showed a remarkable increase in BA delivery to the liver over 99mTc-BA-loaded-LA-free-CL-NPs and 99mTc-BA oral solution. The mean area under the curve (AUC0–24) estimates from liver data were determined to be 11-fold and 26-fold higher from 99mTc-BA-loaded-LA-modified-CL-NPs relative to 99mTc-BA-loaded-LA-free-CL-NPs and 99mTc-BA solution respectively. In conclusion, the outcome of this study highlights the great potential of using LA-modified-CL-NPs for the ultrahigh encapsulation of therapeutic molecules with pH-dependent/poor water-solubility and for targeting the liver.
- 29 January 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 107
Open AccessNanoparticle-Mediated Dual Targeting: An Approach for Enhanced Baicalin Delivery to the Liver
In this study, water-soluble chitosan lactate (CL) was reacted with lactobionic acid (LA), a disaccharide with remarkable affinity to hepatic asialoglycoprotein (ASGP) receptors, to form dual liver-targeting LA-modified-CL polymer for site-specific drug delivery to the liver. The synthesized polymer was used to encapsulate baicalin (BA), a promising bioactive flavonoid with pH-dependent solubility, into ultrahigh drug-loaded nanoparticles (NPs) via the ionic gelation method. The successful chemical conjugation of LA with CL was tested and the formulated drug-loaded LA-modified-CL-NPs were assessed in terms of particle size (PS), encapsulation efficiency (EE) and zeta potential (ZP) using full factorial design. The in vivo biodistribution and pharmacokinetics of the designed NPs were assessed using 99mTc-radiolabeled BA following oral administration to mice and results were compared to 99mTc-BA-loaded-LA-free-NPs and 99mTc-BA solution as controls. Results showed that the chemical modification of CL with LA was successfully achieved and the method of preparation of the optimized NPs was very efficient in encapsulating BA into nearly spherical particles with an extremely high EE exceeding 90%. The optimized BA-loaded-LA-modified-CL-NPs showed an average PS of 490 nm, EE of 93.7% and ZP of 48.1 mV. Oral administration of 99mTc-BA-loaded-LA-modified-CL-NPs showed a remarkable increase in BA delivery to the liver over 99mTc-BA-loaded-LA-free-CL-NPs and 99mTc-BA oral solution. The mean area under the curve (AUC0–24) estimates from liver data were determined to be 11-fold and 26-fold higher from 99mTc-BA-loaded-LA-modified-CL-NPs relative to 99mTc-BA-loaded-LA-free-CL-NPs and 99mTc-BA solution respectively. In conclusion, the outcome of this study highlights the great potential of using LA-modified-CL-NPs for the ultrahigh encapsulation of therapeutic molecules with pH-dependent/poor water-solubility and for targeting the liver.
- 30 November 2019
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 63 (1) , 25-32
Synergistic Cytotoxicity Of Shikonin‐Silver Nanoparticles As An Opportunity For Lung Cancer
The combined action of shikonin and silver nanoparticles (AgNPs) for apoptosis in human cancer cells has not been elucidated. Hence, we investigated the synergistic combinatorial effect of shikonin and AgNPs in human lung cancer cells. Shikonin was used as a reducing and capping agent for AgNPs synthesis as a green method avoiding the hazards of chemical methods. Radiolabeling of shikonin‐AgNPs with radioactive iodine forming [131I]I‐Shikonin‐AgNPs was carried out to enable the intracellular tracking of NPs. The antitumor effect of a combined treatment (shikonin‐AgNPs) was evaluated using tissue culture assay. The 50% inhibitory concentration (IC50) of SHK‐AgNPs on A549 cells after 24 hours determined by an MTT assay is 2.4 ± 0.11 μg/mL. As a deduction, this study revealed that the combination of shikonin and AgNPs treatment significantly inhibited cell viability and proliferation of A549 cells (human lung carcinoma cell line) with a great potential than the monotherapy.
- 30 November 2019
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 63 (1) , 25-32
Synergistic Cytotoxicity Of Shikonin‐Silver Nanoparticles As An Opportunity For Lung Cancer
The combined action of shikonin and silver nanoparticles (AgNPs) for apoptosis in human cancer cells has not been elucidated. Hence, we investigated the synergistic combinatorial effect of shikonin and AgNPs in human lung cancer cells. Shikonin was used as a reducing and capping agent for AgNPs synthesis as a green method avoiding the hazards of chemical methods. Radiolabeling of shikonin‐AgNPs with radioactive iodine forming [131I]I‐Shikonin‐AgNPs was carried out to enable the intracellular tracking of NPs. The antitumor effect of a combined treatment (shikonin‐AgNPs) was evaluated using tissue culture assay. The 50% inhibitory concentration (IC50) of SHK‐AgNPs on A549 cells after 24 hours determined by an MTT assay is 2.4 ± 0.11 μg/mL. As a deduction, this study revealed that the combination of shikonin and AgNPs treatment significantly inhibited cell viability and proliferation of A549 cells (human lung carcinoma cell line) with a great potential than the monotherapy.
- 18 June 2017
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 60 (11) , 542-549
Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique
A novel zoledronic acid (ZL) derivative, 3‐(2‐ethyl‐4‐methyi‐1H‐imidazole‐1‐yl)‐1‐hydroxy‐1‐phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized, and successfully radiolabeled with99mTc. The in vivo biodistribution of99mTc‐EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high‐potential uptake to bone as a promising antiosteoporotic candidate. To further evaluate the bone uptake efficiency, the pharmacokinetics of99mTc‐EMIHPBP was investigated and showed that maximum concentration in bone (Cmax) was 31.60 ± 0.15%ID/gram after 60 minutes (tmax). Cumulative residence of99mTc‐EMIHPBP in the bone [AUC(0−∞)(%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%. Finally, the time needed for half of the99mTc‐EMIHPBP formulation to be eliminated from bone (t1/2) was 263.914 minutes. Excellent bone uptake can be obtained 1‐hour postinjection with high bone/blood ratio of 23.76 detected with gamma counter. The biodistribution and kinetic studies could recommend EMIHPBP as a promising antiosteoporotic candidate with high selectivity to the skeletal system and rapid clearance from soft tissues.
- 18 June 2017
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 60 (11) , 542-549
Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique
A novel zoledronic acid (ZL) derivative, 3‐(2‐ethyl‐4‐methyi‐1H‐imidazole‐1‐yl)‐1‐hydroxy‐1‐phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized, and successfully radiolabeled with99mTc. The in vivo biodistribution of99mTc‐EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high‐potential uptake to bone as a promising antiosteoporotic candidate. To further evaluate the bone uptake efficiency, the pharmacokinetics of99mTc‐EMIHPBP was investigated and showed that maximum concentration in bone (Cmax) was 31.60 ± 0.15%ID/gram after 60 minutes (tmax). Cumulative residence of99mTc‐EMIHPBP in the bone [AUC(0−∞)(%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%. Finally, the time needed for half of the99mTc‐EMIHPBP formulation to be eliminated from bone (t1/2) was 263.914 minutes. Excellent bone uptake can be obtained 1‐hour postinjection with high bone/blood ratio of 23.76 detected with gamma counter. The biodistribution and kinetic studies could recommend EMIHPBP as a promising antiosteoporotic candidate with high selectivity to the skeletal system and rapid clearance from soft tissues.